Eisai to Build New Oral Solid Dose Plant in Suzhou

Eisai Co. of Japan announced plans to build a second new plant in the Suzhou Industrial Park, which will make oral solid dose products. The new facility, which will replace an existing Suzhou plant, will be built next to the parenteral facility that Eisai completed in December. Because Eisai anticipates increased demand for its products in China, the new facility will expand capacity to provide stable supply of oral solid dose drugs, including Methycobal, Aricept and Pariet for the China market. More details.... Stock Symbol: (TO: 4523) Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.